Madopar Retard

Levodopa and benserazide, the active ingredients in Madopar Retard, are a dopamine precursor and a DOPA decarboxylase inhibitor presented as an extended‑release oral tablet for oral use. It treats Parkinson's disease and Parkinsonian syndromes in adults.

GNH USA supplies Madopar Retard as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Madopar Retard is used in the management of dopaminergic deficiency disorders, primarily Parkinsonian conditions.

- Parkinson's disease: improves motor function and reduces rigidity and bradykinesia. - Parkinsonian syndrome: provides symptomatic relief of tremor and stiffness. - Levodopa‑responsive movement disorders: supplies central dopamine to alleviate motor symptoms.

Adverse reactions may occur with any antiparkinson medication. Patients should be aware of both frequent and less common events.

Common Side Effects: - Nausea and vomiting - Orthostatic hypotension - Dizziness or light‑headedness - Insomnia or vivid dreams - Dyskinesia (involuntary movements) - Dry mouth

Serious or Rare Side Effects: - Severe hypertension or hypertensive crisis - Psychotic reactions or hallucinations - Cardiac arrhythmias - Neuroleptic malignant syndrome - Severe allergic reactions (rash, angioedema) - Serotonin syndrome when combined with serotonergic agents

When prescribing Madopar Retard, clinicians should consider several safety measures.

- Dose titration: start with the lowest effective dose and increase gradually. - Monitor blood pressure: watch for orthostatic hypotension, especially in the elderly. - Assess for dyskinesia: adjust dose if involuntary movements develop. - Avoid abrupt discontinuation: sudden stop may worsen Parkinsonian symptoms. - Pregnancy and lactation: safety not established; use only if benefits outweigh risks. - Store at ambient temperature: keep in the original container, protect from moisture.

Drug interactions can modify the efficacy or safety of Madopar Retard and should be reviewed before therapy.

Major Interactions (Avoid):\n- Non‑selective MAO inhibitors: risk of hypertensive crisis. - Irreversible MAO‑B inhibitors without washout (e.g., selegiline): may cause severe hypertension. - Dopamine‑blocking antipsychotics: reduce therapeutic effect.

Moderate Interactions (Monitor Closely): - Antihypertensive agents: additive blood‑pressure lowering. - SSRIs, SNRIs, or tramadol: potential for serotonin syndrome. - Iron or calcium supplements: decrease levodopa absorption. - High‑protein meals: reduce levodopa bioavailability.